The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

European shares closed at a new peak on Tuesday, powered by gains in the healthcare sector, after heavyweight Novo Nordisk ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

Now, it’s worth noting Stock Advisor’s total average return is 975 % — a market-crushing outperformance compared to 193% for ...

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss ...

Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Novo Nordisk secured U.S. regulatory approval for its weight-loss pill, giving the Danish drugmaker a shot at reclaiming ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Novo Nordisk A/S's oral Wegovy wins FDA approval, promising strong 2026 growth with market exclusivity and competitive ...

Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving ​the Danish drugmaker a leg up in the ...

Novo Nordisk shares surged Tuesday after the company said it received FDA approval for an oral version of its injectable weight-loss drug Wegovy.